



Stockholm, Sweden

Press release December 6, 2019

Oncopeptides will host a webcast on Tuesday, December 10th at 13:00 (CET) to provide an update regarding data presented at the ASH annual meeting

Stockholm – December 6, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10th, 2019, at 13:00 (CET) to provide an update regarding the data presented December 7-8 at the American Society Hematology (ASH) Annual Meeting 2019. The webcast will be hosted by CEO Jakob Lindberg.

The webcast can be followed via the link:

<https://tv.streamfabriken.com/oncopeptides-webcast-post-ash>

Participants who would like to ask questions can use the telephone numbers below:

Sweden: + 46 8 56642706

Europe: + 44 3333009270

USA: + 1 8335268384

The presentation can be found at:

<https://oncopeptides.se/en/post-ash-webcast-2019/>

For further information, please contact:

Rein Piir, Head of Investor Relations at Oncopeptides

E-mail: rein.piir@oncopeptides.com

Cell phone: +46 70 853 72 92

This information was submitted for publication at 14:00 CET, December 6, 2019

About Oncopeptides

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides' headquarters is in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

Visit www.oncopeptides.com for more information.